SELECT biomarker_fda_test_trial.test_submission FROM biomarker_fda_test_trial AS biomarker_fda_test_trial JOIN biomarker_fda_test AS biomarker_fda_test ON biomarker_fda_test_trial.test_trade_name = biomarker_fda_test.test_trade_name WHERE biomarker_fda_test.clinical_significance = "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin‐fixed, paraffin‐embedded (FFPE) colorectal cancer (CRC) tissue samples."

###


Original Query:
SELECT T1.test_submission FROM biomarker_fda_test_trial AS T1 JOIN biomarker_fda_test AS T2 ON T1.test_trade_name = T2.test_trade_name WHERE T2.clinical_significance = "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin‐fixed, paraffin‐embedded (FFPE) colorectal cancer (CRC) tissue samples."
GPT-3 choices:
(0) Retrieve the test submissions from the biomarker_fda_test_trial table for all entries in which the clinical significance in the biomarker_fda_test table is "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted
(1) What are the test submissions from the biomarker FDA test trials for the biomarker FDA tests with a clinical significance of "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin‐fixed, par
(2) What is the test submission for biomarker_fda_test_trial where clinical significance is "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin‐fixed, paraffin‐embedded (FFPE
(3) What is the test submission for biomarker FDA test trials where the clinical significance is that the Praxis Extended RAS Panel uses high throughput parallel sequencing to detect 56 specific mutations in KRAS and NRAS genes from DNA extracted from FFPE colorectal cancer tissue samples?
(4) Retrieve the test submissions from the biomarker_fda_test_trial table where the clinical significance of the associated test in the biomarker_fda_test table is "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted
(5) What is the test submission for biomarker FDA test trials where the clinical significance is "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin‐fixed, paraffin‐embedded (FFPE
(6) What are the test submissions from the biomarker_fda_test_trial table where the test trade name is equal to the clinical significance that states "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin
(7) Retrieve the test submission from the biomarker FDA test trial table for all cases where the clinical significance in the corresponding biomarker FDA test table is "The PraxisTM Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formal